DC-STAMP/TM7SF4 Antibodies

204-IL) and 50 ng/mL Recombinant Human GM-CSF (Catalog # 215-GM) for 6 days then treated with 20 ng/mL LPS, 20 ng/mL Recombinant Human TNF-a (Catalog # 210-TA), and 20 ng/mL Recombinant Human IL-1 beta (Catalog # 201-LB) for 24 hours were stained with Mouse Anti-Human CD83 Fluorescein-conjugated Monoclonal Antibody (Catalog # FAB1774F) and either (A) Mouse IgG_2BIsotype Control (Catalog # MAB0041) or (B) Mouse Anti-Human DC-STAMP Monoclonal Antibody (Catalog # MAB7824) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B)." class="big_lightbox"> 204-IL) and 50 ng/mL Recombinant Human GM-CSF (Catalog # 215-GM) for 6 days then treated with 20 ng/mL LPS, 20 ng/mL Recombinant Human TNF-a (Catalog # 210-TA), and 20 ng/mL Recombinant Human IL-1 beta (Catalog # 201-LB) for 24 hours were stained with Mouse Anti-Human CD83 Fluorescein-conjugated Monoclonal Antibody (Catalog # FAB1774F) and either (A) Mouse IgG_2BIsotype Control (Catalog # MAB0041) or (B) Mouse Anti-Human DC-STAMP Monoclonal Antibody (Catalog # MAB7824) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B)." alt="Human mature dendritic cells derived from CD14⁺Human peripheral blood mononuclear cells (PBMCs) treated with 20 ng/mL Recombinant Human IL-4 (Catalog # 204-IL) and 50 ng/mL Recombinant Human GM-CSF (Catalog # 215-GM) for 6 days then treated with 20 ng/mL LPS, 20 ng/mL Recombinant Human TNF-a (Catalog # 210-TA), and 20 ng/mL Recombinant Human IL-1 beta (Catalog # 201-LB) for 24 hours were stained with Mouse Anti-Human CD83 Fluorescein-conjugated Monoclonal Antibody (Catalog # FAB1774F) and either (A) Mouse IgG_2BIsotype Control (Catalog # MAB0041) or (B) Mouse Anti-Human DC-STAMP Monoclonal Antibody (Catalog # MAB7824) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B)." class="big_thumb" />